AGIO up +9.20% percent Today $AGIO High is at 93.00 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 19, 2014 at 10:31 AM

AGIO up +9.20% percent Today $AGIO High is at 93.00 and the Low 83.68 with current volume of 1,516,641.

Recent News posted below.

Agios Pharmaceuticals Inc AGIO other info.
http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/

AGIO Agios Pharmaceuticals Inc Recent Headline News

Stock Futures Take A Data Dive; Tesla Falls On Outlook Change
at Investor's Business Daily - 1 hr 19 mins ago
Stock futures fell out of flat trade to moderate losses ahead of Wednesday's open after a mixed read on October homebuilding activity. Dow futures slumped 18.8 points below fair market value. Nasdaq 100 futures traded down 6.3 points. S&P 500 futures...
SPLS: 13.98 (+1.22), LEJU: 12.45 (-1.71), TSLA: 248.10 (-9.60), FCAU: 12.18 (-0.63), LITB: 7.75 (+0.11), TTM: 46.46 (-0.70), DL: 17.75 (+2.78), VA: 36.84 (-0.21), TGT: 71.07 (+3.56), GM: 32.10 (-0.17), AGIO: 91.55 (+7.74), LOW: 61.76 (+3.23), HMC: 31.03 (-0.62), EJ: 8.66 (-0.87), PETM: 76.40 (+2.78)

Agios leukemia drug candidate shows clinical activity in Phase 1 trial
Seeking Alpha - at Seeking Alpha - 1 hr 29 mins ago

AGIO: 91.55 (+7.74)

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
at The Street - Tue Nov 18, 5:02PM CST
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
AGIO: 91.55 (+7.74), CELG: 106.02 (-0.76)

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Nov 18, 5:01PM CST
-Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -
AGIO: 91.55 (+7.74)

Jim Cramer Says to Buy Six Flags, Avoid SeaWorld Entertainment
at The Street - Wed Nov 12, 1:20PM CST
TheStreet's Jim Cramer says investors shouldn't be tricked by SeaWorld's attractive dividend yield. Instead, stick with Six Flags Entertainment.
SEAS: 17.20 (+0.14), SIX: 40.53 (-0.27), AGIO: 91.55 (+7.74)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 84.37 (-1.19), OREX: 5.54 (-0.08), PCMI: 8.86 (+0.07), CYAN: 7.69 (-0.15), ACHN: 13.10 (-0.21), TGTX: 14.49 (-0.28), AGIO: 91.70 (+7.89), LIOX: 5.05 (-0.09), SAJA: 5.97 (-0.14), PLNR: 7.23 (-0.16)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 170.72 (-0.66), SLXP: 104.96 (-0.43), ICPT: 157.87 (-4.63), IBB: 293.56 (-1.69), AGIO: 91.70 (+7.89)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST

AGIO: 91.70 (+7.89)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.63 (+0.06), ANET: 76.88 (+0.08), TKMR: 16.11 (-0.26), ORBC: 6.21 (-0.13), MDRX: 12.05 (-0.15), RMTI: 9.99 (-0.29), CTIC: 2.22 (-0.06), SHLD: 35.65 (-0.26), UBNT: 29.30 (-0.29), RIG: 25.29 (-0.56), KGC: 2.85 (-0.11), APT: 2.84 (+0.11), ANF: 28.81 (-0.13), MITK: 3.89 (-0.07), ZNGA: 2.68 (-0.03), CNET: 1.83 (-0.03), KING: 16.07 (-0.03), NETE: 1.35 (unch), SLXP: 104.96 (-0.43), RPRX: 9.07 (-0.12), NADL: 3.71 (-0.26), PGNX: 6.41 (-0.13), AVNR: 13.90 (+0.20), FSLR: 49.01 (-0.45), DVA: 74.97 (-0.26), NDLS: 22.55 (-0.10), ICPT: 157.87 (-4.63), AGIO: 91.55 (+7.74), PLNR: 7.23 (-0.16)

Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST

AGIO: 91.60 (+7.79)

Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 91.60 (+7.79)

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 91.60 (+7.79)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 49.66 (-0.22), ERF: 15.01 (-0.14), LXP: 10.96 (-0.01), PGEM: 12.29 (-0.14), CCOI: 34.99 (-0.16), TTI: 7.99 (-0.17), SJI: 56.40 (-0.15), NXST: 47.08 (-0.32), VSAT: 65.70 (+0.16), MT: 12.28 (-0.17), LXU: 33.33 (-0.40), HUM: 138.11 (-1.18), PGNX: 6.41 (-0.13), MHR: 4.55 (-0.07), CTB: 32.52 (unch), IDRA: 2.54 (+0.06), ISIS: 50.00 (+0.29), BPL: 81.59 (+0.19), SSP: 19.61 (-0.03), AGIO: 91.60 (+7.79), EBIX: 16.10 (-0.13)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 84.79 (-4.01), RNA: 11.45 (-0.05), AGIO: 91.72 (+7.91), CELG: 106.03 (-0.75)

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 91.72 (+7.91)

Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 114.63 (-0.75), LNKD: 217.10 (-3.97), HAL: 48.15 (-0.39), AGIO: 91.72 (+7.91), IMPV: 41.32 (-1.21)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 101.71 (-2.00), CLVS: 50.90 (-2.88), ARWR: 5.95 (unch), ACHN: 13.11 (-0.20), MRK: 59.19 (-0.70), RTRX: 8.90 (-0.13), RGLS: 17.32 (-0.80), EPZM: 23.07 (-0.36), AGIO: 91.72 (+7.91), RMTI: 9.99 (-0.29), ARNA: 4.21 (-0.10), KERX: 15.48 (-0.06)

Cramer's Lightning Round - Isis Pharmaceuticals Has The Best Pipeline (10/28/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Oct 29, 5:59AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday October 2 8. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "Isis got slammed, and (the selloff) was overdone. It has the best pipeline...
GS: 189.02 (-0.62), RICE: 25.65 (+0.15), ISIS: 50.00 (+0.29), CYBR: 42.09 (-0.58), GNC: 43.05 (+0.16), HAL: 48.15 (-0.39), AGIO: 91.72 (+7.91), FTNT: 26.55 (-0.40)

'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 46.24 (-0.17), RICE: 25.65 (+0.15), GS: 189.02 (-0.62), FEYE: 31.30 (-0.57), ISIS: 50.00 (+0.29), CYBR: 42.09 (-0.58), GNC: 43.05 (+0.16), HAL: 48.15 (-0.39), EOG: 97.66 (-0.01), AGIO: 91.72 (+7.91), FTNT: 26.55 (-0.40)

Agios Pharmaceuticals Inc. (AGIO) Stock Research Links

AGIO Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leqembi Pen Revolutionizes Alzheimer's Care in Japan

Innovative Alzheimer's Treatment Hits Japanese Market Just when you think the medical world needs a jolt of innovation, BioArctic rolls out something that could change how Alzheimer's is managed. With their subcutaneous Leqembi Pen, they've just added another feather in their cap, launching in Japan after a successful U.S. introduction. Not just your run-of-the-mill...

Randi Baptiste Sets a New Standard in Youth Sports

Youth Sports: Revolutionized by Randi Baptiste In an era where youth sports face a minefield of health risks and performance pressures, Randi Baptiste stands out. This isn't just about running around the park—this is about fundamentally transforming how we think about athletic development for young folks. Recognizing Baptiste for his contributions, The Inner Circle...

Simform's AI Innovations Earns Microsoft Award Nod

Riding the AI Wave with Simform In the chaotic world of AI and tech partnerships, earning recognition from a powerhouse like Microsoft ain't your run-of-the-mill achievement. Simform being recognized as a finalist for the 2026 Microsoft Innovate with Azure AI Apps and Agents Partner of the Year Award is a big deal, not just for them, but as a beacon of inspiration for...

GAC's Green Push Unveils 3rd Showroom in Casablanca

Pushing Through North Africa's Automotive Shift Well, looks like GAC is showing they're not just dabbling in North Africa—they're planting some sturdy roots in that rocky soil. Opening their third showroom in Casablanca, GAC isn't just settling for sidelines. They're step-in-the-ring serious about carving their name on North African roads. This isn't some skin-deep...

Adam Foundation's Ramadan Effort to Cut Plastic Waste

Environmental Consciousness: A Call from Antalya Here we go again, folks. Something refreshing is brewing over in Antalya at COP31, where the UK-based Adam Foundation has made a move that resonates beyond the usual hubbub. No smoke and mirrors, just straightforward action aimed at cutting down the wave of plastic waste during Ramadan. This isn't some pie-in-the-sky green...

FF EAI Robotics Aims for Top Spot in K-12 Tech

FFR's Shot at Robotics Education Dominance You ever feel like a company is throwing everything but the kitchen sink at an opportunity? That's FF EAI Robotics for you—charging ahead with a hefty laundry list of tech ambitions. They've clocked in about $2.3 million in revenue from their newly acquired robotics wing for the first nine months of 2026, showing a 26% gross...

Rethinking Risk: AI, Cyber, and Ops Convergence

Risk Management's New Frontier Hold onto your hats, folks, because the landscape of risk management is shifting under our feet—and not a minute too soon. With AI adoption skyrocketing, cybersecurity threats piling up like never-ending junk mail, and operational hurdles lurking around every corner, Wipfli's throwing down the gauntlet for business leaders to wise up....

Implantica's Q3 2026: A Potential Leap Forward?

Implantica Prepares to Unveil Q3 Results We're heading into the home stretch for 2026, and Implantica's about to unveil its third-quarter results. With its presentation scheduled for November 19 at 15:00 CET, this medtech outfit has caught some eyes, especially with their flagship offering, RefluxStop®. Paying attention here might be worthwhile, as this plays into a...

A New Era of Loyalty Commerce The winds are changing in the loyalty game, and it's about time someone shook things up. Squeez has teamed up with Qentelli, thanks to a $1 million investment, to kick-start this next wave of commerce. And boy, it's not just about money—it's like combining brains with brawn. Squeez isn't just offering loyalty programs anymore; they're...

Vipshop Sets 2026 AGM: Shareholders Meet on Dec 8

Blockbuster or Bust: Vipshop's Upcoming AGM Here's the scoop: Vipshop Holdings Limited, with its mammoth operations in China's off-price retail sector, is gearing up for its annual general meeting (AGM) on December 8, 2026. This is where management and stakeholders will hash out everything from strategic pivots to financial health. Forget shareholder votes this...